Clinical Trials
4 trialsNCT03610971 2026-04-02
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT01702064 2021-01-05
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01914484 2020-11-02
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
Phase 1/2 Completed